Today (Tuesday 2 April 2013) is
World Autism Awareness Day (WAAD).
I don't exactly know how one is supposed to communicate this message ('
Happy world autism awareness day' just doesn't roll off the tongue). So I guess all I will say is to reiterate the subtext of this blog on what the spectrum - the very wide spectrum - means: "
To some it means a need for life-long support. To others it is part of the varied tapestry of humanity. To all it means a need to foster a welcoming society with appropriate support and opportunities."
Onwards. Having discussed the latest paper from Drs Stephen Walker and Arthur Krigsman
on bowel pathology in cases of autism potentially denoting a distinct condition from other inflammatory bowel diseases and stumbling upon
the paper by Peeters and colleagues* on functional defecation disorder and autistic traits, I thought it appropriate to
pop into the DeLorean and revisit a paper which never really received the recognition it deserved.
The subject matter for today is
the paper by Karoly Horvath and colleagues** published in 1999 as we begin another trip down the autism research memory lane, same as I did when covering the
the Mary Goodwin paper from 1971 on the gut-brain axis and autism (
see here) and the John Money autism and autoimmunity paper also from 1971 (
see here).
 |
| Hadrian's Wall @ Wikipedia |
Remember my name
The name Karoly Horvath will probably be familiar to quite a few people who've been on the autism research scene for a while.
Another of Dr Horvath's papers*** created a bit of stir a while back based on some very preliminary findings on the use of the digestive hormone,
secretin for cases of autism.
Following some initial reports of "
transient, marginally significant improvements in autistic behaviors" in some cases as per studies like
the one from Coniglio and colleagues****, a whole slew of subsequent trials have painted a rather less positive picture on the use of secretin for autism as per
the review by Krishnaswami and colleagues***** (open-access) which quite emphatically stated that "
secretin as a treatment approach for ASDs warrants no further study".
I'm not one to normally challenge paper conclusions - particularly systematic reviews - but will perhaps contrast that quote with the closing remarks made by
the Cochrane Library review of Williams and colleagues******. They left the secretin research door slightly ajar for those who were potentially able to identify "
important subgroups of children with ASD who could benefit from secretin because of a proven link between the action of secretin and the known cause of their ASD, or the type of problems they are experiencing". I'm a great believer in subgroups when it comes to autism, or rather the autisms, and how a diagnosis of autism is seemingly protective of nothing when it comes to other conditions/states, so you can perhaps assume which quote was my preference.
Factoids
Anyhow, back to the Horvath 1999 paper. A few interesting factoids from their report:
- Thirty-six children all diagnosed with an autism spectrum disorder (ASD), mean age 5.7 years, formed the participant group. Children were all referred to the gastroenterology (GI) clinic where the authors worked following the presence of various GI symptoms ranging from abdominal pain to chronic diarrhoea and various other presentations.
- As well as quite a bit of review of participants' medical history, various clinical investigations were undertaken which included a "full upper gastrointestinal workup", analysis of digestive enzyme function in the small intestine and some histological examination.
- Results: quite a few important findings. Reflux esophagitis was present in nearly 70% of participants (25/36). Chronic inflammation of the gastric mucosa was determined in 15 children. Reduced disaccharidase activity was present in approximately 60% of children, and in particular low lactase levels. Following administration of secretin, participants with autism and diarrhoea comorbid showed signs of increased pancreatico-biliary fluid output potentially indicative of "upregulation of the secretin receptors" itself potentially related to "either a defect in secretin production or a problem of release from the intestinal S cells".
- "There was no evidence of either fungal or bacterial overgrowth in the duodenum" was another finding.
I know there is a lot to take in from those results so I'm going to try and put them into some kind of perspective with some of the other related literature in the peer-reviewed domain.
Lactose intolerance
I'll start with the disaccharidase activity side of things. The Horvath results were in some respects ahead of their time with their findings in this area. I've talked previously about
the Rafail Kushak paper and their findings of the frequency "
of lactase deficiency was 58% in autistic children ≤ 5 years old and 65% in older patients". Notice the similarity in the percentages between Horvath and Kushak. Indeed, this whole area of carbohydrate malabsorption present in cases of autism was very nicely continued by
the Brent Williams paper looking at enzyme activity and autism. I know a few people have talked about how some of these findings might overlap with for example, the various reports on the use and effectiveness of
a gluten- and casein-free (cereal grains and mammalian dairy free) diet in some cases of autism. Certainly, I wouldn't rule out a possible overlap to account for any results.
Reflux and GERD
Gastroesophageal reflux and reflux esophagitis - states pertaining to
inflammation of the esophagus - were also commonly reported in the participant group and indeed also correlated with various behavioural manifestations noted in some cases (nighttime wakening, signs of irritability, abdominal discomfort) which are "
typically reported by non-autistic children with esophagitis". A little reading around this topic suggests that many cases of such esophagitis are tied into things like
GERD - gastroesophageal reflux disease - which is basically about stomach acid rising up instead of staying where it should be and causing damage. That being said, other explanations have also surfaced to potentially account for the damage done during GERD (
see the paper by Souza and colleagues*******) highlighting a possible role for cytokines in this process. I'm also conscious of the findings of
eosinophilic esophagitis being reported in individual cases of autism (
see here). In terms of management options and without heading down any medical advice giving path, I was very interested to see a body of work appearing
supporting the use of baclofen for cases of GERD********, a derivative of which - arbaclofen - has recently been touted as
a potential intervention option for cases of autism. One has to wonder whether kum-ba-arbaclofen might be doing so much more than just affecting
GABA receptors?
I'm going to stop there with the Horvath paper and its quite important observations. Once again it is a good example of how, just because we see a rising tide of new findings on autism or any other condition or state, we shouldn't neglect the older literature (published pre-social media) and the valuable insights that it has provided. Indeed, I am going to champion the paper by Horvath
et al as an important one; particularly when it came to the assessment of carbohydrate digestive enzyme activity because it was truly ahead of its time and very possibly something that you might hear more about in the coming years of autism research.
Importantly for WAAD, the Horvath paper is a stark reminder that awareness of the autism spectrum should extend beyond just the triad (
very soon to be dyad) of core symptoms and into the range of often very pronounced comorbidities which can also exist and affect quality of life. And just in case you need a more recent example of this, have a look at
this paper from Francisca van Steensel and colleagues********* (open-access) and their findings on the over 50% rate of psychiatric comorbidity reported in their pediatric cohort. Their focus on
'anxiety disorders' does not need any more chatter from me.
To close, something musically, a little more contemporary. Bruno Mars and
Locked Out Of Heaven.
----------
* Peeters B.
et al. Autism spectrum disorders in children with functional defecation disorders.
J Pediatr. March 2013.
** Horvath K.
et al. Gastrointestinal abnormalities in children with autistic disorder.
J Pediatr. 1999; 135: 559-563.
*** Horvath K.
et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders.
J Assoc Acad Minor Phys. 1998; 9: 9-15.
**** Coniglio SJ.
et al. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism.
J Pediatr. 2001; 138: 649-655.
***** Krishnaswami S.
et al. A systematic review of secretin for children with autism spectrum disorders.
Pediatrics. 2011; 127: e1322–e1325.
****** Williams K.
et al. Intravenous secretin for autism spectrum disorders (ASD).
Cochrane Database Syst Rev. 2012; 4: CD003495.
******* Souza RF.
et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury.
Gastroenterology. 2009; 137: 1776-1784.
******** Cossentino MJ.
et al. Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux - a randomised prospective study.
Aliment Pharmacol Ther. March 2012.
********* van Steensel FJA.
et al. Psychiatric comorbidity in children with autism spectrum disorders: a comparison with children with ADHD.
J Child Fam Stud. 2013; 22: 368–376.
----------
Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, & Tildon JT (1999). Gastrointestinal abnormalities in children with autistic disorder. The Journal of pediatrics, 135 (5), 559-63 PMID: 10547242
"Our data support [the] safety and efficacy of baclofen as an adjuvant to risperidone for improvement of hyperactivity symptoms in children with ASD [autism spectrum disorder]."
